Abstract
Alendronate has been shown to prevent osteolysis in a canine total hip arthroplasty (THA) model. However, the effect of alendronate on bone ingrowth and remodeling around canine cementless hip replacement components remains unclear. We hypothesized that oral alendronate would increase net bone ingrowth into the porous surface of THA components when intimate bone/implant contact exists. To test this hypothesis, six mature dogs received unilateral cementless THA and were treated with five milligrams of oral alendronate daily from day seven to day eighty-four postoperatively. Six comparable dogs served as controls. Quantitative analysis of net bone ingrowth into the porous surface did not show a significant difference between the two groups, (control 7.9 ± 1.5, alendronate 7.5 ± 1.4, P < 0.6). These results did not support the hypothesis that oral alendronate would increase net new bone formation into the porous surface of THA components.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
